WO2006094724A3 - Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies - Google Patents

Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies Download PDF

Info

Publication number
WO2006094724A3
WO2006094724A3 PCT/EP2006/001984 EP2006001984W WO2006094724A3 WO 2006094724 A3 WO2006094724 A3 WO 2006094724A3 EP 2006001984 W EP2006001984 W EP 2006001984W WO 2006094724 A3 WO2006094724 A3 WO 2006094724A3
Authority
WO
WIPO (PCT)
Prior art keywords
diffusible
beta oligomers
antibodies
purifying
manufacturing
Prior art date
Application number
PCT/EP2006/001984
Other languages
French (fr)
Other versions
WO2006094724A2 (en
Inventor
Heinz Hillen
Andreas Striebinger
Patrick Keller
Stefan Barghorn
Ulrich Ebert
Original Assignee
Abbott Gmbh & Co Kg
Heinz Hillen
Andreas Striebinger
Patrick Keller
Stefan Barghorn
Ulrich Ebert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006094724(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0608076-6A priority Critical patent/BRPI0608076A2/en
Priority to US11/885,362 priority patent/US20090035295A1/en
Priority to CA002599792A priority patent/CA2599792A1/en
Priority to EP06707413A priority patent/EP1861422B1/en
Priority to NZ560689A priority patent/NZ560689A/en
Priority to DE602006012459T priority patent/DE602006012459D1/en
Priority to MX2007010687A priority patent/MX2007010687A/en
Application filed by Abbott Gmbh & Co Kg, Heinz Hillen, Andreas Striebinger, Patrick Keller, Stefan Barghorn, Ulrich Ebert filed Critical Abbott Gmbh & Co Kg
Priority to AU2006222193A priority patent/AU2006222193B2/en
Priority to AT06707413T priority patent/ATE458754T1/en
Priority to JP2007557444A priority patent/JP4937143B2/en
Publication of WO2006094724A2 publication Critical patent/WO2006094724A2/en
Publication of WO2006094724A3 publication Critical patent/WO2006094724A3/en
Priority to IL185392A priority patent/IL185392A0/en
Priority to ZA2007/07234A priority patent/ZA200707234B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)

Abstract

The present invention is relates to non-diffusible globular Aβ(X - 38 .. 43) oligomers ('globulomers') or derivatives thereof, methods for enriching said globulomers or derivatives, compositions comprising said globulomers or derivatives, antibodies and aptamers having specificity for said globulomers or derivatives, methods for preparing such antibodies and aptamers, uses of said globulomers or derivatives, or of said antibodies or aptamers for diagnostic, therapeutic and other purposes, and corresponding methods using said globulomers or derivatives, or said antibodies or aptamers.
PCT/EP2006/001984 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies WO2006094724A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2007557444A JP4937143B2 (en) 2005-03-05 2006-03-03 Method for detecting autoantibodies having specificity for non-diffusible globular Aβ (X-38..43) oligomeric structural epitopes
MX2007010687A MX2007010687A (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies.
CA002599792A CA2599792A1 (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
EP06707413A EP1861422B1 (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
NZ560689A NZ560689A (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible abeta oligomer, selective antibodies against said non-diffusible abeta oligomers and a process for manufacturing of said antibodies
DE602006012459T DE602006012459D1 (en) 2005-03-05 2006-03-03 SCREENING METHOD, METHOD FOR PURIFYING NON-DIFFINABLE A-BETA OLIGOMERS, SELECTIVE ANTIBODIES AGAINST SUCH NON-DIFFERSIBLE A-BETA OLIGOMERS, AND METHOD FOR PRODUCING THESE ANTIBODIES
AU2006222193A AU2006222193B2 (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
BRPI0608076-6A BRPI0608076A2 (en) 2005-03-05 2006-03-03 selection method, process for purifying non-diffusible beta-a oligomers, selective antibodies against said non-diffusible beta-a oligomers and a process for manufacturing said antibodies
US11/885,362 US20090035295A1 (en) 2005-03-05 2006-03-03 Screening Method, Process for Purifying of Non-Diffusible A-Beta Oligomers, Selective Antibodies Against Said Non-Diffusible a-Beta Oligomers and a Process for Manufacturing of Said Antibodies
AT06707413T ATE458754T1 (en) 2005-03-05 2006-03-03 SCREENING METHOD, METHOD FOR PURIFYING NON-DIFFUSABLE A-BETA OLIGOMERS, SELECTIVE ANTIBODIES AGAINST THESE NON-DIFFUSABLE A-BETA OLIGOMERS AND METHOD FOR PRODUCING THESE ANTIBODIES
IL185392A IL185392A0 (en) 2005-03-05 2007-08-20 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a -beta oligomers and a process for manufacturing of said antibodies
ZA2007/07234A ZA200707234B (en) 2005-03-05 2007-08-27 Screening method,process for purifying of non-diffusible a-beta oligomers,selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP05004858 2005-03-05
EP05004858.6 2005-03-05
US66447705P 2005-03-23 2005-03-23
US60/664,477 2005-03-23
EP05006568.9 2005-03-24
EP05006568 2005-03-24
US74086605P 2005-11-30 2005-11-30
US60/740,866 2005-11-30

Publications (2)

Publication Number Publication Date
WO2006094724A2 WO2006094724A2 (en) 2006-09-14
WO2006094724A3 true WO2006094724A3 (en) 2007-02-15

Family

ID=36581967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/001984 WO2006094724A2 (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies

Country Status (14)

Country Link
US (1) US20090035295A1 (en)
EP (2) EP1861422B1 (en)
KR (1) KR20080021585A (en)
CN (1) CN101365717A (en)
AT (1) ATE458754T1 (en)
AU (1) AU2006222193B2 (en)
BR (1) BRPI0608076A2 (en)
CA (1) CA2599792A1 (en)
DE (1) DE602006012459D1 (en)
ES (1) ES2340414T3 (en)
IL (1) IL185392A0 (en)
MX (1) MX2007010687A (en)
WO (1) WO2006094724A2 (en)
ZA (1) ZA200707234B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5362164B2 (en) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー Prevention and treatment of Alzheimer's disease
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
AU2013200177B2 (en) * 2005-11-30 2014-10-02 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against amyloid beta protein and uses thereof
RU2551782C2 (en) 2005-12-12 2015-05-27 Ац Иммуне Са Anti-amyloid beta (a beta) 1-42 monoclonal antibodies possessing therapeutic properties
JP5033868B2 (en) 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー Improved protofibril selective antibody and use thereof
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
CA2764852C (en) 2007-01-05 2018-09-18 University Of Zurich Method of providing disease-specific binding molecules and targets
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
US7939075B2 (en) 2007-01-11 2011-05-10 Philipps-Universitaet Marburg Human monoclonal anti-amyloid-beta antibodies
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
TW201518320A (en) * 2007-06-12 2015-05-16 Ac Immune Sa Antibody specifically binding to beta amyloid and relevant nucleic acid molecule, expression vector, cell, composition, kit, method, and use
EP2205632B1 (en) * 2007-10-05 2016-11-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
AU2008312802A1 (en) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to abeta oligomer, and use thereof
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
WO2010010469A2 (en) * 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US20110092445A1 (en) * 2008-07-25 2011-04-21 Abbott Laboratories Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
SI2370466T1 (en) 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Human anti-alpha-synuclein autoantibodies
SG10201404913QA (en) 2009-04-09 2014-11-27 Cognition Therapeutics Inc Inhibitors of cognitive decline
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
US8512677B2 (en) 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
CN102595884B (en) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 Inhibitors of cognitive decline
CN102574915B (en) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 Antibodies that specifically bind to A beta oligomers and use thereof
EP2462162B1 (en) 2009-08-06 2016-10-12 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
WO2012054333A2 (en) * 2010-10-20 2012-04-26 Merck Sharp & Dohme Corp. Methods for identifying inhibitors of abeta42 oligomers
JP2014511373A (en) 2011-02-02 2014-05-15 コグニション セラピューティクス インク． Compounds isolated from turmeric oil and methods of use thereof
WO2012120518A1 (en) 2011-03-08 2012-09-13 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (pku)
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
SG10202006762PA (en) 2012-01-27 2020-08-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013138512A1 (en) * 2012-03-13 2013-09-19 Janssen Alzheimer Immunotherapy OLIGOMERIC Aβ IN THE DIAGNOSIS, PROGNOSIS, AND MONITORING OF ALZHEIMER'S DISEASE
ES2721001T3 (en) 2014-01-31 2019-07-26 Cognition Therapeutics Inc Isoindoline derivative, and compositions and methods to treat a neurodegenerative disease
MA40224B1 (en) 2014-07-10 2021-05-31 Eisai R&D Man Co Ltd Antibodies binding to enhanced ass protofibrils
MA41115A (en) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh ALZHEIMER'S DISEASE TREATMENT PROCESS
KR101856838B1 (en) * 2016-02-17 2018-06-19 이희정 Aptamer for beta oligomeric amyloids and uses thereof
CN106519029B (en) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 Preparation process of A β oligomer antibody
KR102614814B1 (en) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 Composition for treating neurodegenerative diseases
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
CN109851668B (en) * 2018-12-26 2022-12-23 广东菲鹏生物有限公司 SAA protein immunogen, preparation method thereof and anti-human serum amyloid A polyclonal antibody
CN111085011B (en) * 2019-12-30 2021-12-03 中南民族大学 Preparation method of molecularly imprinted magnetic nano material and application of molecularly imprinted magnetic nano material in purification of gamma-aminobutyric acid
CN117024554A (en) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 Aβ 1-42 Preparation method and application of oligomer stock solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033815A1 (en) * 1997-02-05 1998-08-06 Northwestern University Amyloid beta protein (globular assembly and uses thereof)
WO2001010900A2 (en) * 1999-08-04 2001-02-15 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
WO2004067561A1 (en) * 2003-01-31 2004-08-12 Abbott Gmbh & Co. Kg Amyloid-$g(b)(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705330A (en) 1995-04-14 1998-01-06 Abbott Laboratories Chemiluminescent immunoassay for antibody detection
DE19916417A1 (en) 1999-04-01 2000-10-19 Schering Ag New amyloid-specific aptamer, useful for diagnosis and/or treatment of e.g. Alzheimer's disease, is stabilized against nucleases
US20020002270A1 (en) * 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
WO2005037209A2 (en) 2003-10-14 2005-04-28 University Of South Florida A method for the separation anti-amyloid beta antibody with amyloid beta peptide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033815A1 (en) * 1997-02-05 1998-08-06 Northwestern University Amyloid beta protein (globular assembly and uses thereof)
WO2001010900A2 (en) * 1999-08-04 2001-02-15 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
WO2004067561A1 (en) * 2003-01-31 2004-08-12 Abbott Gmbh & Co. Kg Amyloid-$g(b)(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C WURTH ET AL.: "Mutations that reduce aggregation of the Alzheimer's AB42 peptide: an unbiased search for the sequence determinants of AB amyloidogenesis", JOURNAL OF MOLECULAR BIOLOGY, vol. 319, 2002, GB LONDON, pages 1279 - 1290, XP004449702 *
G BITAN ET AL.: "Amyloid beta-protein assembly..", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 100, no. 1, 7 January 2003 (2003-01-07), US NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC., pages 330 - 335, XP002281313 *
K N DAHLGREN ET AL.: "Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 35, 30 August 2002 (2002-08-30), US AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., pages 32046 - 32053, XP002281311 *
N. DEMEESTER ET AL.: "Comparison of the aggregation properties, secondary structure and apoptotic effects of the wild-type, Flemish and Dutch N-terminally truncated amyloid beta proteins", EUROPEAN JOURNAL OF NEUROSCIENCE., vol. 13, June 2001 (2001-06-01), GB OXFORD UNIVERSITY PRESS., pages 2015 - 2024, XP002281312 *
S BARGHORN ET AL.: "Globular amyloid beta-peptide 1-42 oligomer - a homogeneous and stable neuropathological protein in Anlzheimer's disease", JOURNAL OF NEUROCHEMISTRY., vol. 95, November 2005 (2005-11-01), US NEW YORK, NY, pages 834 - 847, XP002386548 *
W BLAINE STINE ET AL.: "In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 13, 28 March 2003 (2003-03-28), US AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., pages 11612 - 11622, XP002281314 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
EP2204381A1 (en) 2010-07-07
MX2007010687A (en) 2008-01-28
AU2006222193A1 (en) 2006-09-14
EP1861422A2 (en) 2007-12-05
WO2006094724A2 (en) 2006-09-14
EP1861422B1 (en) 2010-02-24
AU2006222193B2 (en) 2011-11-17
CA2599792A1 (en) 2006-09-14
US20090035295A1 (en) 2009-02-05
DE602006012459D1 (en) 2010-04-08
ATE458754T1 (en) 2010-03-15
ZA200707234B (en) 2011-02-23
BRPI0608076A2 (en) 2009-11-10
KR20080021585A (en) 2008-03-07
ES2340414T3 (en) 2010-06-02
CN101365717A (en) 2009-02-11
IL185392A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
WO2006094724A3 (en) Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2004026254A3 (en) Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
WO2010142423A3 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
WO2006021379A8 (en) Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
WO2006021378A8 (en) Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
WO2005063820A3 (en) Il-7 fusion proteins
WO2006121558A3 (en) Method of prevention and treatment of aging, a related disorders and/or age-related manifestations includi r c erosis.
TW200612985A (en) Immunoglobulins
WO2006000547A3 (en) Method for producing an iron sulfate-based phosphate adsorbent
WO2008083288A3 (en) Purifiction of romidepsin
WO2008049106A3 (en) Process for preparing unaggregated antibody fc domains
SG155046A1 (en) Process for modifying drug crystal formation
NO20061575L (en) Process for the preparation of renzapride and its intermediates
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
WO2009054653A3 (en) Isoindolones with high binding affinity to beta-amyloid aggregates and fibrils, and its use and preparation method
WO2007002722A3 (en) Synthesis of anastrozole and purification of one of its intermediate
WO2007013043A3 (en) Processes for the preparation of 7-amino-3-vinyl cephalosporanic acid
TW200700432A (en) Screening method, process for purifying of non-diffusible a β oligomers, selective antibodies against said non-diffusible a β oligomers and a process for manufacturing of said antibodies
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir
WO2004075860A3 (en) Process for purification of zoledronic acid
WO2004089863A8 (en) Process for the production of 2-hydroxy-4-methylthiobutyric acid ammonium salt
WO2006129120A3 (en) Benzotriazepinone derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015381.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 560689

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 185392

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 6670/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006222193

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010687

Country of ref document: MX

Ref document number: 2599792

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007557444

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006222193

Country of ref document: AU

Date of ref document: 20060303

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006222193

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006707413

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1020077022881

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006707413

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11885362

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0608076

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 204128

Country of ref document: IL